Found: 5
Select item for more details and to access through your institution.
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
- Published in:
- Orphanet Journal of Rare Diseases, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13023-023-02983-0
- By:
- Publication type:
- Article
Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
- Published in:
- Orphanet Journal of Rare Diseases, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13023-023-02700-x
- By:
- Publication type:
- Article
Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
CTA Detection of Left Atrial Stasis and Thrombus in Patients with Atrial Fibrillation.
- Published in:
- Pacing & Clinical Electrophysiology, 2016, v. 39, n. 12, p. 1388, doi. 10.1111/pace.12959
- By:
- Publication type:
- Article
Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
- Published in:
- Orphanet Journal of Rare Diseases, 2022, v. 17, n. 1, p. 1, doi. 10.1186/s13023-022-02587-0
- By:
- Publication type:
- Article